Featured Jobs
|
Sentinel Group
|
|
MAP Retirement
|
|
Retirement Relationship Manager MAP Retirement
|
|
DWC - The 401(k) Experts
|
|
MAP Retirement
|
|
Pattison Pension
|
|
Plan Administrator, Defined Benefit & Cash Balance The Pension Source
|
|
Defined Benefit Plan Consultant/Actuarial Analyst Sentinel Group
|
|
BPAS
|
|
Regional Vice President, Sales MAP Retirement
|
|
Strategic Retirement Plan Consultant Retirement Plan Consultants
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
Semaglutide and Tirzepatide for Obesity: Effectiveness and Value (PDF)
Institute for Clinical and Economic Review [ICER] 
Oct. 31, 2025 244 pages. "Despite these therapies being highly cost-effective, their potential budget impact is large.... [F]ewer than 1% of eligible patients could be treated at current and assumed net prices before crossing the ICER budget impact threshold of $880,000,000 annually. This raises serious concerns about affordability." MORE >> |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |